© John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Edited By: Thomas A. Luger and Ralf Paus
Impact Factor: 3.762
ISI Journal Citation Reports © Ranking: 2014: 7/63 (Dermatology)
Online ISSN: 1600-0625
Instructions to authors
Presubmission inquiries should be sent to:
Thomas A. Luger
Department of Dermatology
University Hospital Münster
D-48149 Münster, Germany
Manchester, UK and Münster, Germany
Institute of Inflammation and Repair
University of Manchester
Manchester M13 9PT, UK
Production Editor: email@example.com
Effective with the 2013 volume, Experimental Dermatology will be published in an online-only format. No printed edition will be published. Your article will therefore appear online-only. All normal author benefits and services remain in place e.g. authors will continue to be able to order print reprints of articles if required.
Print subscription and single issue sales are available from Wiley’s Print-on-Demand Partner. To order online click here http://www.sheridan.com/LPM/Wiley
OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, click here. Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from here. Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.
NEW: Online production tracking is now available for your article through Wiley-Blackwell’s Author Services.
Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production so they don’t need to contact the production editor to check on progress. Visit Author Services for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.
Regular research articles should not exceed 4000 words, not including tables, figures and references.
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the WileyAuthor Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:
For authors choosing OnlineOpenIf the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services.
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements.
For more information on this policy and the journal’s compliant self-archiving policy please click here.
Additionally. authors are themselves responsible for obtaining permission to reproduce copyright material from other sources.
Manuscripts describing studies involving animals should comply with local/national guidelines governing the use of experimental animals and contain a statement indicating that the procedures have been approved by the appropriate regulatory body. Manuscripts concerned with human studies must contain statements indicating that informed, written consent has been obtained, that studies have been performed according to the Declaration of Helsinki and that the procedures have been approved by a local ethics committee. If individuals might be identified from a publication (e.g. from images) authors must obtain explicit consent from the individual.
Prior to submission, authors should carefully check the Ethical guidelines document available here.
Experimental Dermatology is only accepting manuscripts electronically via an online submission site,
ScholarOne Manuscripts (formerly known as Manuscript Central). The use of an online submission and peer review site will speed the time to decisions, enable immediate distribution and allow authors to track their own manuscripts. To access this system for submission and review, go directly to EXD Manuscript Central.
Experimental Dermatology employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.
Manuscripts should be submitted online at Manuscript Central. Full instructions and support are available on the site and a user ID and password can be obtained on the first visit. Support can be contacted by phone ( 1 434 817 2040 ext. 167) Monday-Friday, or at http://mcv3support.custhelp.com.
Conflicts of Interest
When submitting a manuscript, authors are responsible for disclosing all financial and personal relationships that could be viewed as presenting a potential conflict of interest. To prevent ambiguity, all authors must state explicitly whether potential conflicts do or do not exist. This information should be included in the paper after the Acknowledgements section. In the event where there are no conflicts of interest to declare, authors must still include a statement in the paper to say so.
Whenever possible, authors are strongly encouraged to emphasize the clinical relevance of their work. In original papers, at least the final paragraph of the paper should include a discussion of the potential clinical relevance of the presented findings, whenever this makes sense.
All submissions must be accompanied by a short cover letter, which contains the following information: a) definition of the publication category for which the manuscript is being submitted b) statement whether this is an unsolicited submission or has been invited by one of the editors/associate editors or editorial board members (name) c) statement that the applicable author guidelines for this publication category have been fully respected (or, if not, justification why the manuscript should have e.g. an excess word count or number of figs./refs. etc. ) d) brief, but instructive synthesis that explains in which way the current manuscript advances the field (max. 150 words) e) 5 key words that are most relevant to the contents of submitted manuscript and that are not contained in the manuscript title (these are also to be stated on the title page of the manuscript itself) f) recommendation of 3-4 recognized expert reviewers in the specific field(s) of research of the submitted manuscript g) statement that none of the suggested referees has co-authored a publication during the past 4 years with any if the co-authors of the submitted manuscript.
Research Articles may not exceed 4000 words, not including tables, figures & references. They should contain a maximum of 4 display items in single column width (including figures and tables). Clinical studies are explicitly welcome, if they also contain major experimental research components. Please list the word count and number of display items on the cover page of the manuscript. Manuscripts exceeding these limits will be returned to Authors without review. Each manuscript component should begin on a new page in the following sequence: title page; abstract; key words (3 to 5); introduction; methods; results; discussion; acknowledgments; references; tables (each table, complete with title and footnotes, on a separate page); legends for illustrations. Number pages consecutively, beginning with the title page. Type the page number in the upper right-hand corner of each page. Number the tables consecutively with arabic numerals. For any further details, consult the 'Uniform requirements for manuscripts submitted to bio-medical journals'', Ref. (2) below.
Experimental Dermatology regularly publishes Methodological Reviews that provide state-of-the-art, authoritative coverage of important laboratory techniques across all areas of investigative dermatology and molecular biomedicine. These critical reviews also cover typical problems and limitations encountered with the discussed method, suggest problem solving approaches, and offer pragmatic advice from experienced laboratory practitioners not only for newcomers but also readers interested in the field. The submission of Methods Reviews, is invited by the Editors. If you are interested in writing a Methods Review, please contact the Editors. Methods Review: maximum of 3,000 words, plus 2 color plates, 1-2 tables and up to 100 references.
Speculative, thought-provoking Viewpoint essays (max. 2500 words, 100 refs.) and standard review articles (max. 4000 words, 200 refs.) are invited by the editors or associate editors. These always welcome specific suggestions for topics and prospective authors, ideally along with submission of a brief structural outline. Instructions for the design of Viewpoints essays and Review articles are available from the editorial office and details are negotiated with the editors.
Patterns of Expression
Patterns of Expression is a category of paper reporting the comprehensive pattern of expression of a new or important gene during embryonic development and/or in the adult organism, highlighting interesting or unexpected findings. Patterns of Expression papers should contain data using multiple complimentary approaches, including but not limited to, in situ hybridization, immunohistochemistry, immunofluorescence, real-time PCR, western and northern blot. Papers should not exceed 2,500 words and do not require an invitation by the Editor. Documentation should be stringently restricted to what is really essential in order to convincingly document the reported expression pattern. Non-essential, Supporting Information, also in color, may be displayed free-of-charge on the journal website.
Letter to the Editor, Methods Letters to the Editor
Letters and Methods Letters to the Editors in Experimental Dermatology are to be organised as follows: 1000 words: structured into BACKGROUND, QUESTIONS ADDRESSED, EXP. DESIGN, RESULTS, CONCLUSIONS; maximum 2 small figures or tables and 9 references (unlimited number of supplementary references, to be cited as s1, s2, etc. in the Letter manuscript and to be listed only in the supporting information); no abstract; our letter format also allows for essentially unlimited online supplementary data (including more extensive information on materials and methods, more figures/tables and additional references). Please note that LETTERS and METHODS LETTERS TO THE EDITORS must not exceed 2 online print pages including images/tables. As a special service to authors and readers, in contrast to full original articles, LETTERS and METHODS LETTERS TO THE EDITORS in Exp Dermatol are made freely available to all readers so as to render them maximally accessible (free access policy).The title of the Letter should be phrased as a statement headline that transports a clear take home message, which is well-supported by the presented data.
HYPOTHESIS LETTERS offer a forum for the proposal of novel hypotheses on important skin research topics of general interest. These hypotheses must be developed on the basis of the published literature, must be stated clearly and succinctly, and must be experimentally testable. Hypotheses manuscripts that, if confirmed, are likely to lead to important changes in dermatological therapy and/or pathobiology concepts are favored. Hypothesis Letters have a maximum of 900 words, 1 composite figure, 9 references, and can be complemented by an extensive supplement (with additional figs., text, and unlimited number of supplementary references, to be cited as s1, s2, etc. in the Letter manuscript and to be listed only in the supporting information); An abstract is required (max 150 words). They are to be structured as follows: Background, Premises, Hypothesis, How to test the hypothesis, Relevance and perspectives.The title of the Letter should be phrased as a statement headline that transports a clear take home message, which is well-supported by the presented data.
Letter: Mouse Mutants with Absent/Minimal Skin Phenotype
This new publication category features genetic mouse manipulations in the skin (e.g. transgenic gene over/misexpression or gene targeted ablation) that manifest a minimal or no detectable phenotype. Typically a considerable amount of funding resources, research time and effort by students/postdocs has been invested to generate the necessary preliminary data before abandoning a genetic mouse manipulation on project that yields no or only a minimal phenotype. In addition, several labs may embark on similar genetic mouse manipulation efforts with "negative" results, multiplying the loss of money/time resources if the results are not reported. This new letter category will serve as a platform to share such findings by reporting high-quality data that document successful gene manipulation at the RNA/protein level with several complementary methods, such as in situ hybridization, immunofluorescence/histochemistry, genotyping and real-time PCR of isolated cells, and an in-depth "absence of phenotype" analysis of skin tissues at relevant time points (including rigorous quantifications) using tissue stains and cell-type specific gene marker analysis. Letters should be less than 1000 words with a maximum of 2 figures and 9 references and an abstract with 150 words is required. Additional figures, materials, and methods are allowed in a generous "Supporting Information" section.The title of the Letter should be phrased as a statement headline that transports a clear take home message, which is well-supported by the presented data.
This novel type of LETTER is intended to close a long-existing gap between classical case reports, hypothesis letters and viewpoints. To date, case reports are only considered in Experimental Dermatology if they contain a substantial experimental data component. Instead, "BEDSIDE-TO-BENCH LETTERS" can now be used as a unique platform for bridging clinical and experimental dermatology by calling attention to intriguing and instructive clinical cases that shed light on disease pathobiology or novel skin biology aspects. The key characteristic for a case report manuscript to be eligible for publication in Experimental Dermatology as a "BEDSIDE-TO-BENCH LETTER" is that the authors can develop a clear-cut strategy for experimental research that emanates from the case they are reporting and that promises important advances in translational skin biology or skin pathology. For example, a clinician observing an unexpected improvement of a skin disease by a novel biologic or targeted treatment that was initiated to treat another disease of the patient, or who observes an interesting skin sign or symptom that raises fundamental questions on basic skin biology or pathology which can be addressed in a well-defined set of experiments, is strongly invited to transform this observation into a "BEDSIDE-TO-BENCH LETTER". The structure of this innovative type of LETTER manuscript must include (1) a concise presentation of the case supported by key photographic documentation ideally together with histology or immunohistology ( = bedside aspect), (2) proposal of the obtained novel insight into disease pathogenesis, skin biology, or new treatment strategy, and (3) detailed outline of a translational research program (= bench). The maximum length of this "BEDSIDE-TO-BENCH LETTER" is 800 words with 1 composite figure and 9 references. Authors are encouraged to make use of an extensive e-supplement with additional text, figures, tables and references. Like all LETTERS in Experimental Dermatology, this new LETTER category will be freely accessible via PubMed without the need to have a subscription to the journal and thus enjoys unusually good public visibility.The title of the Letter should be phrased as a statement headline that transports a clear take home message, which is well-supported by the presented data.
Comments on papers (incl. Letters) published in Experimental Dermatology during the past 4 months; Commentaries are typically invited, but unsolicited commentaries are welcome
Labeled as COMMENTARY or COMMENTARY FROM THE EDITORIAL BOARD (where applicable)
Cite the study you comment on within the text (Exp Derm abbreviated citation style)
Word limit: 800-1100 words, inclusion of a figure/cartoon and/or table is welcome
The max. number of refs. is 9 (unlimited number of supplementary references, to be cited as s1, s2, etc. in the Commentary manuscript and to be listed only in the supporting information)
essentially unlimited supplement for additional text, figs., tables, refs.
max. online print number of pages including images/tables/references: 2
Commentary: My favorite historical paper
This new publication category features short commentaries that call attention to a seminal historical paper (i.e. original article, review, letter, or book chapter), which currently is not widely known or cited any longer and which the author feels strongly should be brought back to the attention of a wide range of readers and disciplines. Title: needs to attract attention of both experts and non-cognoscenti; must indicate the relevant field of skin research, and should encapsulate at least a first hint at why this paper is important. Text: 600-1000 words, up to 9 references, 1 figure or table and unlimited supplement. The commentary should argue succinctly why the author feels that the selected historical paper is fascinating; has made a major contribution to its field of research and/or is very important for other reasons of general interest. Please elaborate also how this paper has provided major novel concepts or very important pointers that remain pertinent today and are relevant for future research in this area. Ideally, the author should obtain permission from the relevant publisher to reprint the entire historical article in the supplement of the commentary so that the full historical paper becomes easily and generally accessible.
Authors are invited to submit a short video/Podcast (up to 7 minutes). The content should include an overview about the publication and the novelty of it. The videos/Podcasts are produced by the authors and are subject to the editor’s approval before publication. The editor may request revisions if necessary. For further information on recommended file types and requirements for submission, please visit Author Services.
All figures should clarify the text and their number should be kept to a minimum. Details must be large enough to retain their
clarity after reduction. Illustrations should preferably fill single column width (81 mm) after reduction, although in exceptional cases 2/3 width (120 mm) or full page width (168 mm) will be accepted. Line drawings should be professionally drafted and photographed; halftones should exhibit high contrast. A linear size scale should be incorporated into electron microscopic pictures. Colour illustrations will be accepted free of charge.
Abbreviations and Symbols
Use only standard abbreviations. All units will be metric. Use no roman numerals in the text. In decimals, a decimal point, and not a comma, will be used. Consult the CBE style manual: a guide for authors, editors and publishers in the biological sciences, 4th edition, Arlington, Virginia, 1978. Avoid abbreviations in the title. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement. Units of measurement should be expressed in accordance with the SI and CIE recommendations (see Ref. 3, below).
Number references consecutively in the order in which they appear first in the text. Identify references in text, tables and
legends by Arabic numerals (in parentheses). All references cited, and only these, must be listed at the end of the paper. Article titles given in the reference list are to be deleted. Journal litles have to be abbreviated without dots and no comma after the journal title.
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission or during the review process. For further information go to Author Services .
The corresponding author will receive an email alert containing a link to a web site. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from Adobe.
This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Further instructions will be sent with the proof. Hard copy proofs will be posted if no e-mail address is available. Excessive changes made by the author in the proofs, excluding typesetting errors, will be charged separately.
Free access to the final PDF offprint of your article will be available via author services only. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers’.
Author material archive policy. Please note that unless specifically requested, Wiley will dispose of all hardcopy or electronic material submitted 2 months after publication. If you require the return of any material submitted, please inform the editorial office or production editor as soon as possible if you have not yet done so.
Note to NIH Grantees
Pursuant to NIH mandate, Wiley will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see www.wiley.com/go/nihmandate.
The journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
Disclaimer. The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information
contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher and Editors of the products advertised.